Reltecimod sodium
Reltecimod sodium (AB-103 sodium) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod sodium has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod sodium modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod sodium can be used to research necrotizing soft-tissue infections (NSTIs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1943755-99-4
- Formule: C46H71N10NaO15S
- Masse moléculaire:1059.17
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)[2]
-
Dosage:1.25 or 5 mg/kg
-
Administration:i.v.; single dosage; at 4 h post infection
-
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.
Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)[2]
-
Dosage:2.5 or 5 mg/kg
-
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
-
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.
Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.
Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2]
-
Dosage:1.25, 2.5, or 5 mg/kg
-
Administration:i.v.; single dosage
-
Result:Increased day 7 survival by up to 100%.
Chemical Information
-
CAS No. 1943755-99-4
-
Masse moléculaire 1059.17
-
Formule C46H71N10NaO15S
-
Synonyms
AB-103 sodium
-
Sequence
{d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala}
-
Sequence Shortening
{d-Ala}-SPMLVAYD-{d-Ala}
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Reltecimod sodium Related Classifications
HY-P1698A Related Classifications
Powered by Bioz